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Research into practice:
prompt diagnosis of cancer in primary care
Greg Rubin, Fiona Walter, Jon Emery, Richard Neal, Willie Hamilton and Jane Wardle 
Clinical Intelligence
PolICy baCkgRound
Earlier diagnosis of symptomatic cancer 
has become increasingly recognised as 
holding the key to better cancer outcomes. 
Many Western governments have prioritised 
actions to achieve earlier diagnosis of cancer. 
England revised its cancer policy in 2007 
to address this, with a National Awareness 
and Early Diagnosis Initiative (NAEDI) to 
drive forward research, development, and 
service improvement. Actions to improve 
care in England were led by the National 
Cancer Action Team (NCAT) through Cancer 
Networks (now NHS Improving Quality and 
Strategic Clinical Networks), with GP cancer 
leads playing a key role to influence general 
practices. Public awareness of cancer has 
been raised through a sustained programme 
of media campaigns, currently led by Public 
Health England. 
The purpose of this article is to show how 
research to improve diagnosis of symptomatic 
cancer undertaken by the authors, together 
and in collaboration with others, has influenced 
policy and practice. Close engagement with 
the research community has been a feature 
of NAEDI throughout, and the research of this 
collaborative group has been supported via a 
designated NAEDI funding stream, through 
an National Institute for Health Research 
funded programme grant (DISCOVERY), 
and through the Department of Health’s 
Policy Research Unit for Cancer Awareness, 
Screening and Early Diagnosis.
PublIC awaReness of CanCeR 
symPtoms
The Cancer Reform Strategy identified public 
awareness of ‘cancer warning signs’ and 
attitudes to help seeking as key domains for 
promoting early diagnosis. This resulted in 
development of a validated instrument, the 
Cancer Awareness Measure (CAM),1 followed 
by the Awareness and Beliefs about Cancer 
scale (ABC), which added questions on beliefs.2 
The first national CAM survey found low public 
awareness of warning signs, with average 
recall of 2.4 symptoms, and most responders 
recalling only ‘lump’. Awareness was lower in 
men, the younger and oldest age-groups, and 
people of lower socioeconomic status and 
from ethnic minority backgrounds, and also 
that lower awareness was associated with 
greater anticipated delay in help seeking.1 
Fear of ‘wasting the doctor’s time’ was also 
identified as a barrier to prompt help seeking, 
with international comparisons showing it to 
be substantially higher in the UK.2 
The CAM was used widely around the UK 
to benchmark awareness and barriers and to 
inform local public health initiatives, and has 
also been used internationally. The results 
led to an ongoing programme of campaigns 
to raise symptom awareness and encourage 
help seeking, under the ‘Be Clear on Cancer’ 
(BCOC) banner. Recent results from repeat 
CAM surveys have shown clear evidence 
of effects on awareness, although less on 
attitudes to visiting the GP. Campaign effects 
have also been seen on GP consultations, use 
of diagnostic tests, and urgent referrals for 
suspected cancer, and preliminary results 
also suggest an impact on stage of diagnosis 
for lung cancer. 
An early NAEDI action was a programme 
of research to better understand the process 
of cancer diagnosis in primary care. Over 
1100 practices participated in one of the 
largest cancer audits ever undertaken in 
primary care, contributing data on 19 000 
patients. It found that 80% or more of patients 
were referred to a specialist after one or 
two appointments, contributing to the public 
debate on timeliness of cancer referral. There 
was considerable variation between cancers, 
in the length of time patients took before 
deciding to consult3 and in the number of 
consultations before referral.4 These findings 
informed government action to improve GP 
access to diagnostic tests for cancer in 2011 
and have since influenced the choice of target 
cancers for BCOC.
Detailed insights into the diagnostic 
challenges faced by GPs were gained through 
the use of Significant Event Audit (SEA) in 
Cancer Network-wide studies of specified 
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cancers. Using novel methods of analysis, key 
themes emerged of clinical complexity as a 
cause of delay and the importance of safety 
netting in the consultation.5 
Finally, a General Practice Research 
Database study quantified for the first time 
the interval from the first presentation to 
diagnosis for 15 common cancers and 
showed that this had reduced between 2001 
and 2007, probably as a result of National 
Institute of Health and Care Excellence 
(NICE) guidance on urgent referral for 
suspected cancer.6 
Building on these findings, NCAT 
predicated funding to Cancer Networks 
to support primary care on the specific 
encouragement of safety netting, practice 
plans, and the use of our SEA and clinical 
audit tools. In Wales, SEA for lung and upper 
gastrointestinal cancer became part of 
the Quality and Productivity domain of the 
Quality and Outcomes Framework. A practice 
Cancer Toolkit was also commissioned by 
NCAT to support these practice improvement 
activities. By April 2013, 16% of practices 
in England had made cancer plans, 19% 
had used the SEA tool, 21% had done a 
cancer audit, and 9% had implemented safety 
netting. Practices taking up one or more of 
these initiatives referred more patients for 
suspected cancer and showed less variation 
in their referral practice.7 
RIsk of CanCeR
Over the past 8 years, the authors have 
systematically identified and quantified the 
risk of cancer when a patient describes 
symptoms to their GP.8 Risk Assessment 
Tools (RATs) are the main product of that 
work. They were first provided by NCAT to 
GPs in 152 pilot practices in 2010, in the 
form of mousemats and desktop flipcharts. 
In an evaluation at the time, their use was 
associated with increased urgent referrals; 
47 additional lung and 10 additional colorectal 
cancers were identified, some of favourable 
staging.9 In 2012 they were provided to all 
practices in England and have now been 
adopted by NICE in the revision of their 
guidance for GPs. Alongside risk prediction 
algorithms developed by researchers in 
Nottingham, they lie behind an electronic 
cancer decision support tool for suspected 
cancer, promoted by Macmillan Cancer 
Support. RATs are also being disseminated in 
Denmark and underpin cluster randomised 
controlled trials in Western Australia and 
England.
Current thresholds for referral or 
investigation range from a 2% risk upwards, 
depending on cancer site. They are largely 
implicit and determined by clinicians and 
policymakers. On the other hand, patient views 
elicited through their responses to clinical 
vignettes indicate that, for lung, colorectal, 
and pancreatic cancer, more than 80% would 
want to be investigated for suspected cancer 
even when the risk was as low as 1%.10 
ReseaRCH metHodology
Studies of cancer diagnostic pathways 
are best conducted if they apply explicit 
methodological frameworks and report their 
findings consistently. Based on a systematic 
review of cancer studies that had applied 
the Andersen Model of Total Patient Delay, 
we developed the Model of Pathways to 
Treatment (Figure 1). This model is now widely 
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figure 1. model of pathways to treatment.  
HCP = healthcare practitioner. Reproduced with 
permission of sage Publications ltd.  
© walter, 2012.11
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used. It identifies key intervals and processes 
along the cancer diagnostic and treatment 
pathway and recognises the importance of 
patient, health system, and tumour factors in 
time to diagnosis and treatment.11
In addition, the Department of Health 
and Cancer Research UK commissioned 
a landmark consensus statement on 
the conduct and reporting of studies of 
symptomatic diagnostic journeys.12 Its 
recommendations regarding methods and 
definitions are being widely adopted and 
should improve the quality of the evidence 
base in this area, making findings more 
transparent and comparable.
dIagnostIC teCHnologIes
There is significant interest in the potential of 
a range of diagnostic technologies to support 
early cancer diagnosis in primary care. Our 
work in melanoma diagnosis has trialled 
various diagnostic aids. The MoleMate Trial 
compared the use of a new imaging device, 
based on a technique called SIAscopy, 
against systematic application of the 7-point 
checklist (7-PCL). The authors found no 
difference between these two approaches in 
terms of appropriate referrals to urgent skin 
cancer clinics or in detection of melanoma.13 
The authors were also the first to validate the 
7-PCL in a primary care setting, suggesting 
that a cut-off score of 4 rather than 3 may be 
more accurate. The 7-PCL has been added 
to the Macmillan electronic cancer decision 
support tool for suspected cancer, and its 
effect on GP management of suspicious 
pigmented lesions is being studied using 
thickness of melanoma at diagnosis (a key 
determinant of prognosis) as the outcome 
measure.
InteRnatIonal ComPaRIsons
Cancer policymakers in the UK have always 
eyed mainland Europe with envy. It is now 
well accepted that our comparatively poor 
cancer outcomes are real, and, at least in 
part, based on an greater willingness on 
the part of primary care physicians in those 
countries to investigate for possible cancer. 
An ecological study showed a clear inverse 
relationship between 1-year relative survival 
after cancer diagnosis and three principles of 
gatekeeping systems, including the GP as the 
first point of contact.14 Denmark, a country 
with a closely comparable primary care 
system to the UK, has dramatically addressed 
this, liberalising access to cancer diagnostics, 
both directly and by referral, with guidance 
that roughly equates to ‘if the GP suspects 
cancer, refer’: a stance very different to that of 
NICE and Scottish Intercollegiate Guidelines 
Network guidance in the UK. Results are 
eagerly awaited from this policy decision, with 
early indicators suggesting that diagnostic 
intervals have fallen modestly (comparable 
to the reductions seen in the UK when the 
urgent referral pathways were introduced).6 
Also imminent are the findings of a survey of 
GPs in 11 jurisdictions in the UK, Scandinavia, 
Canada and Australia. This has mapped 
out what cancer diagnostic facilities those 
GPs have access to, and has elicited their 
readiness to proceed to test or referral using 
clinical vignettes: the hypothesis being that 
jurisdictions with better 1 and 5 year cancer 
survival rates will also have GPs who would 
investigate for cancer sooner.
 
wHat’s neXt?
Our findings, particularly on patient 
preference and differences in clinical practice, 
have informed the recent announcement 
by England’s National Director of Cancer 
Services of a programme that will accelerate 
and coordinate NHS initiatives to improve 
diagnostic pathways, and be rigorously 
evaluated. It is likely that England will adopt 
some features of the Danish model, but with 
more emphasis on local solutions. 
Novel biomarkers may assist in diagnosing 
symptomatic cancer earlier by adding value 
to other diagnostic tests and symptoms 
profiles. In due course they may also have 
value in case-finding in higher risk but pre-
symptomatic individuals to find early stage 
disease that can be treated more effectively. 
They may also be used to risk-stratify 
‘higher-risk’ groups for which specific risk 
reduction and primary prevention strategies 
are appropriate.
Clinical decision support (CDS) may evolve 
from its current narrow focus on specific 
cancers. Two members of this group are 
now collaborating with German experts in 
artificial intelligence and complex thinking, 
and with London Cancer, on the development 
of a next-generation electronic CDS tool that 
utilises a sophisticated artificial intelligence 
approach.
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